-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Xilio Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q3 2020 to Q3 2025.
- Xilio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $1.12M, a 28.7% decline year-over-year.
- Xilio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $5.53M, a 19.3% decline year-over-year.
- Xilio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6.43M, a 12.8% decline from 2023.
- Xilio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7.38M, a 12.4% decline from 2022.
- Xilio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8.42M, a 69.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)